The Experts in Animal Health

printer friendly

Brakke Consulting’s
Animal Health News & Notes for October 9, 2015

Copyright © Brakke Consulting, Inc.
Editor: Lynn Fondon DVM MBA
Brakke Consulting news
earnings news
other news
AniCell Biotech
Boehringer Ingelheim
IsoRay Medical
Kinetic Vet
Pacific Vet Group-USA
The best place on the web to find qualified job applicants! is now in its 9th year of operation. It has become an exceptional and mature capability for your recruiting efforts. has grown to include over 27,000 pre-qualified job seekers, and consistently maintains a high degree of talent: 66% of our registered users have a Bachelor’s degree, and 21% have some kind of advanced degree. has recently achieved new records for the number of job postings on the site, so when you are seeking the best, come to – first. 

> Cargill reported results for its fiscal 2016 first quarter ended August 31. The company reported net earnings of $512 million for the fiscal first quarter ending August 31, a 20% increase compared with a year earlier. Revenue was down 17% to $27.5 billion. Adjusted operating earnings in Animal Nutrition & Protein decreased in the first quarter, with increased results in animal nutrition offset by lower earnings in animal protein. (company website) 
> Jaguar Animal Health reported results for the second quarter of 2015. Revenues were $63,000 compared to $0 in the second quarter of 2014. The net loss was $(5.3 million) compared to a net loss of $(1.9 million) last year. (company website)

Last week’s newsletter incorrectly identified Modern Veterinary Therapeutics’ new Canadian ketoprofen product as Ketoprofen VTM. The product’s correct name is Ketoprofen V.
> Elanco Animal Health announced the introduction of Onsior injection, which can be used interchangeably with Onsior tablets to effectively control postoperative pain and inflammation. Onsior provides 24 hours of pain relief with once-a-day administration for up to a maximum of three days. (company press release)
> Kinetic Vet announced the launch of Kera-Mend Hoof Dressing. Kera-Mend Hoof Dressing contains vitamins and minerals to stimulate rapid, high quality hoof growth, along with sodium hyaluronate for moisturizing. (company press release)  
> Novozymes announced the acquisition of Pacific Vet Group-USA, Inc. (PVG). PVG develops and produces probiotics for animals, and has significant know-how in probiotic applications for poultry, strong development expertise, a pipeline for the poultry hatchery segment, and a smaller commercial product portfolio. Financial terms were not disclosed. ( 
> Neutricks announced the launch of a soft chew for dogs. Neutricks Soft Chews will be available in veterinary clinics starting next month. (Vet Advantage)
> AniCell Biotech launched the EquusCell Brand of regenerative products used for treating tendon and ligament damage in horses as well as treating hard-to-heal superficial and ocular wounds. This product uses mesenchymal stem cell components from amniotic material collected non-invasively during the parturition of healthy foals. (company press release)
> IsoRay Medical announced the introduction of its FDA-cleared Cesium-131 LDR seed brachytherapy for the treatment of cancerous tumors in animals to approved veterinary radiation oncologists and facilities. (company press release)
> JAPAN  Zoetis announced the Japanese Ministry of Agriculture, Forestry and Fisheries (JMAFF) has approved Apoquel tablets (oclacitinib maleate) for improvement of inflammation caused by atopic dermatitis and relief of pruritus associated with allergic dermatitis in dogs. (Animal Pharm)
> AUSTRALIA  The Australian Pesticides and Veterinary Medicines Authority (APVMA) has approved Boehringer Ingelheim’s Semintra (telmisartan1) oral solution for cats. Semintra is an angiotensin receptor blocker indicated for the reduction in proteinuria in cats with chronic kidney disease. (Animal Pharm)  
> WORLD – KETAMINE  The World Health Organization (WHO) is considering a proposed change to the international scheduling of ketamine to a Schedule 1 drug, which could mean that it would no longer be available to US veterinarians. Consequently, the FDA has issued a request for comments on the availability for medical use of 10 drug substances including ketamine. The comments will be considered as FDA prepares a response to the WHO regarding the abuse liability and diversion of these drugs. Comments are due to the FDA by Oct. 15; to comment, follow the instructions onthe FDA website: . (AVMA)
> US – PEDv  The USDA believes it has found the source of the porcine epidemic diarrhea virus (PEDv) that swept through US swine operations beginning in 2013. The virus was nearly identical in DNA to a similar illness in China and was likely carried into the US via tote bags used in international trade. The agency was not able to come up with definitive proof that a shipping bag was the source of the virus. (FierceAnimalHealth)
> US – CONTRACEPTION RESEARCH  Researchers at the California Institute of Technology have created a vaccine that inhibited reproduction in mice. The vaccine delivers DNA that directs the animals’ muscle cells to make antibodies against gonadotropin-releasing hormone. The researchers also produced a vaccine that creates antibodies against the zona pellucida, making eggs impervious to sperm. The researchers plan next to test the vaccine in cats. (AVMA SmartBrief –
> US – CANCER GENE Researchers from eight US and international institutions of veterinary and human medicine have identified genes involved in canine lymphoma. The team studied the somatic mutations in B- and T-cell lymphomas from golden retrievers, cocker spaniels, and boxers by exome sequencing of tumor. The results were published in Genome Research. (Vet Advantage – AAHA NEWstat)
> US – CANCER INSTITUTE  The Animal Medical Center (AMC) in New York City unveiled its new Cancer Institute, made possible through a $5 million gift from AMC Trustees Elaine and Kenneth G. Langone. (PRNewswire)
This week’s newsletter has several smaller stories but one very important one for the veterinary community. The World Health Organization is considering a proposed change to schedule ketamine as a Schedule 1 drug. This could have a dramatic impact on the availability of this drug for use by veterinarians. This appears to be another international restriction related to the uses of various drugs in animals.
There continues to be increasing pressure on the use of old and new drugs in veterinary medicine for what often seems to be little or no reason. With a limited number of new drugs becoming available for the practicing veterinarian, it is important that older drugs that in some cases have been used for decades be maintained in the marketplace for use by veterinarians, unless there is new evidence that these drugs are harmful and there are safer drugs available to replace them.

Have a great weekend!

Ron Brakke

This electronic newsletter is the sole property of Brakke Consulting, Inc.
Any use of the contents herein should be approved by and appropriately attributed to Brakke Consulting, Inc.
For more information about Brakke Consulting’s services and syndicated studies, visit our website at
Brakke Consulting, Inc.
12005 Ford Rd., Suite 530
Dallas, TX  75234    USA


en_USEnglish (United States)